nodes	percent_of_prediction	percent_of_DWPC	metapath
Bromocriptine—CYP1A2—Imiquimod—skin cancer	0.119	0.196	CbGbCtD
Bromocriptine—ABCB1—Vismodegib—skin cancer	0.072	0.119	CbGbCtD
Bromocriptine—CYP1A2—Vemurafenib—skin cancer	0.0651	0.107	CbGbCtD
Bromocriptine—CYP3A4—Temozolomide—skin cancer	0.0623	0.103	CbGbCtD
Bromocriptine—CYP3A4—Imiquimod—skin cancer	0.0623	0.103	CbGbCtD
Bromocriptine—CYP1A2—Dacarbazine—skin cancer	0.0499	0.0824	CbGbCtD
Bromocriptine—CYP3A4—Vismodegib—skin cancer	0.0432	0.0712	CbGbCtD
Bromocriptine—ABCB1—Dactinomycin—skin cancer	0.0378	0.0624	CbGbCtD
Bromocriptine—CYP3A4—Vemurafenib—skin cancer	0.0341	0.0563	CbGbCtD
Bromocriptine—CYP1A2—Fluorouracil—skin cancer	0.0293	0.0483	CbGbCtD
Bromocriptine—DRD5—eyelid—skin cancer	0.0207	0.212	CbGeAlD
Bromocriptine—ABCB1—Docetaxel—skin cancer	0.0195	0.0322	CbGbCtD
Bromocriptine—CYP3A4—Docetaxel—skin cancer	0.0117	0.0193	CbGbCtD
Bromocriptine—DRD1—nerve—skin cancer	0.00422	0.0431	CbGeAlD
Bromocriptine—HTR2A—hindlimb—skin cancer	0.0027	0.0276	CbGeAlD
Bromocriptine—HTR1B—blood vessel—skin cancer	0.00269	0.0274	CbGeAlD
Bromocriptine—HTR7—nerve—skin cancer	0.00264	0.0269	CbGeAlD
Bromocriptine—HTR1D—blood vessel—skin cancer	0.0026	0.0265	CbGeAlD
Bromocriptine—DRD2—nerve—skin cancer	0.00249	0.0254	CbGeAlD
Bromocriptine—HTR2A—appendage—skin cancer	0.00232	0.0237	CbGeAlD
Bromocriptine—HTR7—endothelium—skin cancer	0.00225	0.0229	CbGeAlD
Bromocriptine—HTR7—blood vessel—skin cancer	0.00207	0.0211	CbGeAlD
Bromocriptine—ADRA1D—epithelium—skin cancer	0.00169	0.0173	CbGeAlD
Bromocriptine—HTR2A—nerve—skin cancer	0.00164	0.0168	CbGeAlD
Bromocriptine—DRD5—lymphoid tissue—skin cancer	0.00163	0.0166	CbGeAlD
Bromocriptine—DRD5—female reproductive system—skin cancer	0.00157	0.016	CbGeAlD
Bromocriptine—HTR7—neck—skin cancer	0.00148	0.0151	CbGeAlD
Bromocriptine—HTR2A—endothelium—skin cancer	0.0014	0.0143	CbGeAlD
Bromocriptine—DRD3—head—skin cancer	0.0014	0.0143	CbGeAlD
Bromocriptine—ADRA2C—nipple—skin cancer	0.00138	0.014	CbGeAlD
Bromocriptine—HTR6—head—skin cancer	0.00135	0.0137	CbGeAlD
Bromocriptine—HTR1D—connective tissue—skin cancer	0.00133	0.0136	CbGeAlD
Bromocriptine—DRD5—head—skin cancer	0.00131	0.0134	CbGeAlD
Bromocriptine—ADRB1—connective tissue—skin cancer	0.0013	0.0132	CbGeAlD
Bromocriptine—HTR2A—blood vessel—skin cancer	0.00129	0.0132	CbGeAlD
Bromocriptine—ADRA1D—female reproductive system—skin cancer	0.00126	0.0128	CbGeAlD
Bromocriptine—CYP1A2—nipple—skin cancer	0.00119	0.0122	CbGeAlD
Bromocriptine—HTR2B—skin of body—skin cancer	0.00112	0.0114	CbGeAlD
Bromocriptine—ADRA2A—nipple—skin cancer	0.0011	0.0112	CbGeAlD
Bromocriptine—ADRA1B—head—skin cancer	0.00107	0.011	CbGeAlD
Bromocriptine—HTR7—connective tissue—skin cancer	0.00106	0.0108	CbGeAlD
Bromocriptine—ADRA1D—head—skin cancer	0.00105	0.0107	CbGeAlD
Bromocriptine—HTR7—epithelium—skin cancer	0.00101	0.0103	CbGeAlD
Bromocriptine—DRD1—head—skin cancer	0.001	0.0102	CbGeAlD
Bromocriptine—ADRA1A—epithelium—skin cancer	0.000972	0.00992	CbGeAlD
Bromocriptine—HTR1B—female reproductive system—skin cancer	0.000971	0.00991	CbGeAlD
Bromocriptine—HTR1D—female reproductive system—skin cancer	0.00094	0.00959	CbGeAlD
Bromocriptine—HTR2C—female reproductive system—skin cancer	0.000931	0.0095	CbGeAlD
Bromocriptine—Mental disorder—Imiquimod—skin cancer	0.00093	0.00406	CcSEcCtD
Bromocriptine—HTR2A—neck—skin cancer	0.000924	0.00943	CbGeAlD
Bromocriptine—Diplopia—Temozolomide—skin cancer	0.000919	0.00402	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000916	0.004	CcSEcCtD
Bromocriptine—ADRB1—female reproductive system—skin cancer	0.000914	0.00932	CbGeAlD
Bromocriptine—Vomiting—Vismodegib—skin cancer	0.00091	0.00398	CcSEcCtD
Bromocriptine—Rash—Vismodegib—skin cancer	0.000902	0.00394	CcSEcCtD
Bromocriptine—Dermatitis—Vismodegib—skin cancer	0.000901	0.00394	CcSEcCtD
Bromocriptine—Dysphagia—Dactinomycin—skin cancer	0.000878	0.00384	CcSEcCtD
Bromocriptine—Infection—Vemurafenib—skin cancer	0.000878	0.00384	CcSEcCtD
Bromocriptine—HTR2B—female reproductive system—skin cancer	0.000875	0.00892	CbGeAlD
Bromocriptine—Nervous system disorder—Vemurafenib—skin cancer	0.000867	0.00379	CcSEcCtD
Bromocriptine—Ataxia—Temozolomide—skin cancer	0.000864	0.00378	CcSEcCtD
Bromocriptine—Lethargy—Fluorouracil—skin cancer	0.000864	0.00378	CcSEcCtD
Bromocriptine—Skin disorder—Vemurafenib—skin cancer	0.000859	0.00375	CcSEcCtD
Bromocriptine—Nausea—Vismodegib—skin cancer	0.00085	0.00372	CcSEcCtD
Bromocriptine—Agitation—Imiquimod—skin cancer	0.000849	0.00371	CcSEcCtD
Bromocriptine—Gastrointestinal haemorrhage—Fluorouracil—skin cancer	0.000847	0.0037	CcSEcCtD
Bromocriptine—ABCB1—blood vessel—skin cancer	0.000846	0.00863	CbGeAlD
Bromocriptine—Syncope—Imiquimod—skin cancer	0.000828	0.00362	CcSEcCtD
Bromocriptine—Acute coronary syndrome—Bleomycin—skin cancer	0.000828	0.00362	CcSEcCtD
Bromocriptine—Hypotension—Vemurafenib—skin cancer	0.000826	0.00361	CcSEcCtD
Bromocriptine—Myocardial infarction—Bleomycin—skin cancer	0.000823	0.0036	CcSEcCtD
Bromocriptine—Loss of consciousness—Imiquimod—skin cancer	0.000812	0.00355	CcSEcCtD
Bromocriptine—HTR1B—head—skin cancer	0.000811	0.00828	CbGeAlD
Bromocriptine—ADRA2C—mammalian vulva—skin cancer	0.000804	0.0082	CbGeAlD
Bromocriptine—Convulsion—Imiquimod—skin cancer	0.0008	0.0035	CcSEcCtD
Bromocriptine—Hypertension—Imiquimod—skin cancer	0.000797	0.00349	CcSEcCtD
Bromocriptine—Ataxia—Fluorouracil—skin cancer	0.000796	0.00348	CcSEcCtD
Bromocriptine—Dysphagia—Temozolomide—skin cancer	0.000794	0.00347	CcSEcCtD
Bromocriptine—HTR1D—head—skin cancer	0.000785	0.00801	CbGeAlD
Bromocriptine—Anxiety—Imiquimod—skin cancer	0.000784	0.00343	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000781	0.00342	CcSEcCtD
Bromocriptine—ADRA2A—connective tissue—skin cancer	0.000779	0.00795	CbGeAlD
Bromocriptine—HTR2C—head—skin cancer	0.000778	0.00794	CbGeAlD
Bromocriptine—Dry mouth—Imiquimod—skin cancer	0.000769	0.00336	CcSEcCtD
Bromocriptine—Decreased appetite—Vemurafenib—skin cancer	0.000768	0.00336	CcSEcCtD
Bromocriptine—ADRB1—head—skin cancer	0.000763	0.00779	CbGeAlD
Bromocriptine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000763	0.00334	CcSEcCtD
Bromocriptine—Fatigue—Vemurafenib—skin cancer	0.000762	0.00333	CcSEcCtD
Bromocriptine—Nasopharyngitis—Fluorouracil—skin cancer	0.000757	0.00331	CcSEcCtD
Bromocriptine—Constipation—Vemurafenib—skin cancer	0.000756	0.00331	CcSEcCtD
Bromocriptine—Oedema—Imiquimod—skin cancer	0.000754	0.0033	CcSEcCtD
Bromocriptine—Lightheadedness—Docetaxel—skin cancer	0.000753	0.00329	CcSEcCtD
Bromocriptine—Hypoaesthesia—Bleomycin—skin cancer	0.00075	0.00328	CcSEcCtD
Bromocriptine—ADRA1A—lymphoid tissue—skin cancer	0.000749	0.00764	CbGeAlD
Bromocriptine—HTR7—female reproductive system—skin cancer	0.000749	0.00764	CbGeAlD
Bromocriptine—Infection—Imiquimod—skin cancer	0.000749	0.00327	CcSEcCtD
Bromocriptine—Shock—Imiquimod—skin cancer	0.000742	0.00324	CcSEcCtD
Bromocriptine—Nervous system disorder—Imiquimod—skin cancer	0.000739	0.00323	CcSEcCtD
Bromocriptine—Tachycardia—Imiquimod—skin cancer	0.000736	0.00322	CcSEcCtD
Bromocriptine—Pollakiuria—Temozolomide—skin cancer	0.000734	0.00321	CcSEcCtD
Bromocriptine—Skin disorder—Imiquimod—skin cancer	0.000732	0.0032	CcSEcCtD
Bromocriptine—Dysphagia—Fluorouracil—skin cancer	0.000732	0.0032	CcSEcCtD
Bromocriptine—HTR2B—head—skin cancer	0.000731	0.00745	CbGeAlD
Bromocriptine—Anorexia—Imiquimod—skin cancer	0.000719	0.00314	CcSEcCtD
Bromocriptine—Body temperature increased—Vemurafenib—skin cancer	0.000699	0.00306	CcSEcCtD
Bromocriptine—Insomnia—Imiquimod—skin cancer	0.000682	0.00298	CcSEcCtD
Bromocriptine—Paraesthesia—Imiquimod—skin cancer	0.000677	0.00296	CcSEcCtD
Bromocriptine—Cardiac failure congestive—Docetaxel—skin cancer	0.000674	0.00295	CcSEcCtD
Bromocriptine—Dyspnoea—Imiquimod—skin cancer	0.000672	0.00294	CcSEcCtD
Bromocriptine—Somnolence—Imiquimod—skin cancer	0.00067	0.00293	CcSEcCtD
Bromocriptine—Alopecia—Bleomycin—skin cancer	0.000666	0.00291	CcSEcCtD
Bromocriptine—Sinusitis—Temozolomide—skin cancer	0.000665	0.00291	CcSEcCtD
Bromocriptine—Dyspepsia—Imiquimod—skin cancer	0.000664	0.0029	CcSEcCtD
Bromocriptine—HTR2A—connective tissue—skin cancer	0.000662	0.00676	CbGeAlD
Bromocriptine—Decreased appetite—Imiquimod—skin cancer	0.000655	0.00287	CcSEcCtD
Bromocriptine—HTR1A—head—skin cancer	0.000655	0.00668	CbGeAlD
Bromocriptine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000651	0.00285	CcSEcCtD
Bromocriptine—Fatigue—Imiquimod—skin cancer	0.00065	0.00284	CcSEcCtD
Bromocriptine—Visual disturbance—Docetaxel—skin cancer	0.000645	0.00282	CcSEcCtD
Bromocriptine—Acute coronary syndrome—Fluorouracil—skin cancer	0.000643	0.00281	CcSEcCtD
Bromocriptine—ADRA2A—mammalian vulva—skin cancer	0.000641	0.00654	CbGeAlD
Bromocriptine—Myocardial infarction—Fluorouracil—skin cancer	0.00064	0.0028	CcSEcCtD
Bromocriptine—Asthenia—Vemurafenib—skin cancer	0.000634	0.00277	CcSEcCtD
Bromocriptine—Hallucination—Temozolomide—skin cancer	0.000633	0.00277	CcSEcCtD
Bromocriptine—Hypoaesthesia—Temozolomide—skin cancer	0.000633	0.00277	CcSEcCtD
Bromocriptine—HTR2A—epithelium—skin cancer	0.000629	0.00641	CbGeAlD
Bromocriptine—Oedema peripheral—Temozolomide—skin cancer	0.000626	0.00274	CcSEcCtD
Bromocriptine—HTR7—head—skin cancer	0.000626	0.00638	CbGeAlD
Bromocriptine—Connective tissue disorder—Temozolomide—skin cancer	0.000625	0.00273	CcSEcCtD
Bromocriptine—Lethargy—Docetaxel—skin cancer	0.000624	0.00273	CcSEcCtD
Bromocriptine—Alopecia—Dactinomycin—skin cancer	0.000621	0.00272	CcSEcCtD
Bromocriptine—Feeling abnormal—Imiquimod—skin cancer	0.000621	0.00272	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Imiquimod—skin cancer	0.000616	0.0027	CcSEcCtD
Bromocriptine—Visual impairment—Temozolomide—skin cancer	0.000613	0.00268	CcSEcCtD
Bromocriptine—Sinusitis—Fluorouracil—skin cancer	0.000612	0.00268	CcSEcCtD
Bromocriptine—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000611	0.00267	CcSEcCtD
Bromocriptine—Diarrhoea—Vemurafenib—skin cancer	0.000605	0.00264	CcSEcCtD
Bromocriptine—ADRA1A—head—skin cancer	0.000604	0.00616	CbGeAlD
Bromocriptine—Urticaria—Imiquimod—skin cancer	0.000599	0.00262	CcSEcCtD
Bromocriptine—Abdominal pain—Imiquimod—skin cancer	0.000596	0.00261	CcSEcCtD
Bromocriptine—Body temperature increased—Imiquimod—skin cancer	0.000596	0.00261	CcSEcCtD
Bromocriptine—Eye disorder—Temozolomide—skin cancer	0.000594	0.0026	CcSEcCtD
Bromocriptine—Tinnitus—Temozolomide—skin cancer	0.000593	0.00259	CcSEcCtD
Bromocriptine—DRD2—head—skin cancer	0.000592	0.00603	CbGeAlD
Bromocriptine—Cardiac disorder—Temozolomide—skin cancer	0.00059	0.00258	CcSEcCtD
Bromocriptine—Rhinitis—Fluorouracil—skin cancer	0.000587	0.00257	CcSEcCtD
Bromocriptine—Dizziness—Vemurafenib—skin cancer	0.000585	0.00256	CcSEcCtD
Bromocriptine—Hypoaesthesia—Fluorouracil—skin cancer	0.000583	0.00255	CcSEcCtD
Bromocriptine—Angiopathy—Temozolomide—skin cancer	0.000577	0.00252	CcSEcCtD
Bromocriptine—ADRA2C—head—skin cancer	0.000575	0.00587	CbGeAlD
Bromocriptine—Ataxia—Docetaxel—skin cancer	0.000575	0.00251	CcSEcCtD
Bromocriptine—Mediastinal disorder—Temozolomide—skin cancer	0.000573	0.00251	CcSEcCtD
Bromocriptine—Vomiting—Vemurafenib—skin cancer	0.000562	0.00246	CcSEcCtD
Bromocriptine—Alopecia—Temozolomide—skin cancer	0.000562	0.00246	CcSEcCtD
Bromocriptine—Abdominal pain upper—Docetaxel—skin cancer	0.000558	0.00244	CcSEcCtD
Bromocriptine—Orthostatic hypotension—Docetaxel—skin cancer	0.000558	0.00244	CcSEcCtD
Bromocriptine—Rash—Vemurafenib—skin cancer	0.000557	0.00244	CcSEcCtD
Bromocriptine—Mental disorder—Temozolomide—skin cancer	0.000557	0.00244	CcSEcCtD
Bromocriptine—Dermatitis—Vemurafenib—skin cancer	0.000557	0.00243	CcSEcCtD
Bromocriptine—Headache—Vemurafenib—skin cancer	0.000554	0.00242	CcSEcCtD
Bromocriptine—Cramp muscle—Docetaxel—skin cancer	0.00055	0.00241	CcSEcCtD
Bromocriptine—ADRA2A—female reproductive system—skin cancer	0.000549	0.0056	CbGeAlD
Bromocriptine—Nasopharyngitis—Docetaxel—skin cancer	0.000547	0.00239	CcSEcCtD
Bromocriptine—Dysgeusia—Temozolomide—skin cancer	0.000542	0.00237	CcSEcCtD
Bromocriptine—Asthenia—Imiquimod—skin cancer	0.000541	0.00237	CcSEcCtD
Bromocriptine—Confusional state—Bleomycin—skin cancer	0.00054	0.00236	CcSEcCtD
Bromocriptine—Oedema—Bleomycin—skin cancer	0.000536	0.00234	CcSEcCtD
Bromocriptine—Infection—Bleomycin—skin cancer	0.000532	0.00233	CcSEcCtD
Bromocriptine—Dysphagia—Docetaxel—skin cancer	0.000528	0.00231	CcSEcCtD
Bromocriptine—Nausea—Vemurafenib—skin cancer	0.000525	0.0023	CcSEcCtD
Bromocriptine—Arrhythmia—Fluorouracil—skin cancer	0.000523	0.00229	CcSEcCtD
Bromocriptine—Vision blurred—Temozolomide—skin cancer	0.000522	0.00228	CcSEcCtD
Bromocriptine—Alopecia—Fluorouracil—skin cancer	0.000518	0.00226	CcSEcCtD
Bromocriptine—Diarrhoea—Imiquimod—skin cancer	0.000516	0.00226	CcSEcCtD
Bromocriptine—HTR2B—lymph node—skin cancer	0.000512	0.00522	CbGeAlD
Bromocriptine—Anorexia—Bleomycin—skin cancer	0.00051	0.00223	CcSEcCtD
Bromocriptine—Agitation—Temozolomide—skin cancer	0.000509	0.00222	CcSEcCtD
Bromocriptine—Hypotension—Bleomycin—skin cancer	0.0005	0.00219	CcSEcCtD
Bromocriptine—Oedema—Dactinomycin—skin cancer	0.000499	0.00218	CcSEcCtD
Bromocriptine—Dizziness—Imiquimod—skin cancer	0.000499	0.00218	CcSEcCtD
Bromocriptine—Vertigo—Temozolomide—skin cancer	0.000497	0.00217	CcSEcCtD
Bromocriptine—Infection—Dactinomycin—skin cancer	0.000496	0.00217	CcSEcCtD
Bromocriptine—Paraesthesia—Bleomycin—skin cancer	0.000481	0.0021	CcSEcCtD
Bromocriptine—Vision blurred—Fluorouracil—skin cancer	0.000481	0.0021	CcSEcCtD
Bromocriptine—Convulsion—Temozolomide—skin cancer	0.00048	0.0021	CcSEcCtD
Bromocriptine—Vomiting—Imiquimod—skin cancer	0.000479	0.0021	CcSEcCtD
Bromocriptine—Hypertension—Temozolomide—skin cancer	0.000478	0.00209	CcSEcCtD
Bromocriptine—Dyspnoea—Bleomycin—skin cancer	0.000477	0.00209	CcSEcCtD
Bromocriptine—Anorexia—Dactinomycin—skin cancer	0.000476	0.00208	CcSEcCtD
Bromocriptine—Rash—Imiquimod—skin cancer	0.000475	0.00208	CcSEcCtD
Bromocriptine—Dermatitis—Imiquimod—skin cancer	0.000475	0.00208	CcSEcCtD
Bromocriptine—Headache—Imiquimod—skin cancer	0.000472	0.00207	CcSEcCtD
Bromocriptine—Anxiety—Temozolomide—skin cancer	0.00047	0.00205	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000468	0.00205	CcSEcCtD
Bromocriptine—HTR2A—female reproductive system—skin cancer	0.000467	0.00476	CbGeAlD
Bromocriptine—Decreased appetite—Bleomycin—skin cancer	0.000466	0.00204	CcSEcCtD
Bromocriptine—Acute coronary syndrome—Docetaxel—skin cancer	0.000464	0.00203	CcSEcCtD
Bromocriptine—Myocardial infarction—Docetaxel—skin cancer	0.000462	0.00202	CcSEcCtD
Bromocriptine—Dry mouth—Temozolomide—skin cancer	0.000461	0.00202	CcSEcCtD
Bromocriptine—ADRA2A—head—skin cancer	0.000459	0.00468	CbGeAlD
Bromocriptine—Confusional state—Temozolomide—skin cancer	0.000456	0.00199	CcSEcCtD
Bromocriptine—Oedema—Temozolomide—skin cancer	0.000452	0.00198	CcSEcCtD
Bromocriptine—Infection—Temozolomide—skin cancer	0.000449	0.00196	CcSEcCtD
Bromocriptine—Nausea—Imiquimod—skin cancer	0.000448	0.00196	CcSEcCtD
Bromocriptine—Nervous system disorder—Temozolomide—skin cancer	0.000443	0.00194	CcSEcCtD
Bromocriptine—Convulsion—Fluorouracil—skin cancer	0.000442	0.00193	CcSEcCtD
Bromocriptine—Feeling abnormal—Bleomycin—skin cancer	0.000441	0.00193	CcSEcCtD
Bromocriptine—Skin disorder—Temozolomide—skin cancer	0.000439	0.00192	CcSEcCtD
Bromocriptine—Decreased appetite—Dactinomycin—skin cancer	0.000434	0.0019	CcSEcCtD
Bromocriptine—CYP3A4—female reproductive system—skin cancer	0.000432	0.00441	CbGeAlD
Bromocriptine—Fatigue—Dactinomycin—skin cancer	0.000431	0.00188	CcSEcCtD
Bromocriptine—Anorexia—Temozolomide—skin cancer	0.000431	0.00188	CcSEcCtD
Bromocriptine—Urticaria—Bleomycin—skin cancer	0.000425	0.00186	CcSEcCtD
Bromocriptine—Rhinitis—Docetaxel—skin cancer	0.000424	0.00185	CcSEcCtD
Bromocriptine—Body temperature increased—Bleomycin—skin cancer	0.000423	0.00185	CcSEcCtD
Bromocriptine—Hypoaesthesia—Docetaxel—skin cancer	0.000421	0.00184	CcSEcCtD
Bromocriptine—Confusional state—Fluorouracil—skin cancer	0.00042	0.00184	CcSEcCtD
Bromocriptine—Oedema peripheral—Docetaxel—skin cancer	0.000417	0.00182	CcSEcCtD
Bromocriptine—Oedema—Fluorouracil—skin cancer	0.000416	0.00182	CcSEcCtD
Bromocriptine—Connective tissue disorder—Docetaxel—skin cancer	0.000416	0.00182	CcSEcCtD
Bromocriptine—Infection—Fluorouracil—skin cancer	0.000414	0.00181	CcSEcCtD
Bromocriptine—ABCB1—epithelium—skin cancer	0.000412	0.0042	CbGeAlD
Bromocriptine—Feeling abnormal—Dactinomycin—skin cancer	0.000412	0.0018	CcSEcCtD
Bromocriptine—Insomnia—Temozolomide—skin cancer	0.000409	0.00179	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000408	0.00179	CcSEcCtD
Bromocriptine—Nervous system disorder—Fluorouracil—skin cancer	0.000408	0.00178	CcSEcCtD
Bromocriptine—Visual impairment—Docetaxel—skin cancer	0.000408	0.00178	CcSEcCtD
Bromocriptine—Tachycardia—Fluorouracil—skin cancer	0.000406	0.00178	CcSEcCtD
Bromocriptine—Paraesthesia—Temozolomide—skin cancer	0.000406	0.00177	CcSEcCtD
Bromocriptine—Dyspnoea—Temozolomide—skin cancer	0.000403	0.00176	CcSEcCtD
Bromocriptine—ADRA2C—lymph node—skin cancer	0.000403	0.00411	CbGeAlD
Bromocriptine—Somnolence—Temozolomide—skin cancer	0.000402	0.00176	CcSEcCtD
Bromocriptine—Dyspepsia—Temozolomide—skin cancer	0.000398	0.00174	CcSEcCtD
Bromocriptine—Anorexia—Fluorouracil—skin cancer	0.000397	0.00173	CcSEcCtD
Bromocriptine—Eye disorder—Docetaxel—skin cancer	0.000395	0.00173	CcSEcCtD
Bromocriptine—Abdominal pain—Dactinomycin—skin cancer	0.000395	0.00173	CcSEcCtD
Bromocriptine—Body temperature increased—Dactinomycin—skin cancer	0.000395	0.00173	CcSEcCtD
Bromocriptine—Decreased appetite—Temozolomide—skin cancer	0.000393	0.00172	CcSEcCtD
Bromocriptine—Cardiac disorder—Docetaxel—skin cancer	0.000392	0.00172	CcSEcCtD
Bromocriptine—HTR2A—head—skin cancer	0.00039	0.00398	CbGeAlD
Bromocriptine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00039	0.00171	CcSEcCtD
Bromocriptine—Fatigue—Temozolomide—skin cancer	0.000389	0.0017	CcSEcCtD
Bromocriptine—Hypotension—Fluorouracil—skin cancer	0.000389	0.0017	CcSEcCtD
Bromocriptine—Constipation—Temozolomide—skin cancer	0.000386	0.00169	CcSEcCtD
Bromocriptine—Asthenia—Bleomycin—skin cancer	0.000384	0.00168	CcSEcCtD
Bromocriptine—Angiopathy—Docetaxel—skin cancer	0.000384	0.00168	CcSEcCtD
Bromocriptine—Mediastinal disorder—Docetaxel—skin cancer	0.000381	0.00167	CcSEcCtD
Bromocriptine—Arrhythmia—Docetaxel—skin cancer	0.000378	0.00165	CcSEcCtD
Bromocriptine—Insomnia—Fluorouracil—skin cancer	0.000376	0.00165	CcSEcCtD
Bromocriptine—Paraesthesia—Fluorouracil—skin cancer	0.000374	0.00163	CcSEcCtD
Bromocriptine—Alopecia—Docetaxel—skin cancer	0.000374	0.00163	CcSEcCtD
Bromocriptine—Feeling abnormal—Temozolomide—skin cancer	0.000372	0.00163	CcSEcCtD
Bromocriptine—Dyspnoea—Fluorouracil—skin cancer	0.000371	0.00162	CcSEcCtD
Bromocriptine—Mental disorder—Docetaxel—skin cancer	0.00037	0.00162	CcSEcCtD
Bromocriptine—Somnolence—Fluorouracil—skin cancer	0.00037	0.00162	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Temozolomide—skin cancer	0.000369	0.00162	CcSEcCtD
Bromocriptine—Dyspepsia—Fluorouracil—skin cancer	0.000366	0.0016	CcSEcCtD
Bromocriptine—Decreased appetite—Fluorouracil—skin cancer	0.000362	0.00158	CcSEcCtD
Bromocriptine—Dysgeusia—Docetaxel—skin cancer	0.00036	0.00158	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000359	0.00157	CcSEcCtD
Bromocriptine—Urticaria—Temozolomide—skin cancer	0.000359	0.00157	CcSEcCtD
Bromocriptine—Asthenia—Dactinomycin—skin cancer	0.000358	0.00157	CcSEcCtD
Bromocriptine—ABCB1—mammalian vulva—skin cancer	0.000357	0.00365	CbGeAlD
Bromocriptine—Abdominal pain—Temozolomide—skin cancer	0.000357	0.00156	CcSEcCtD
Bromocriptine—Body temperature increased—Temozolomide—skin cancer	0.000357	0.00156	CcSEcCtD
Bromocriptine—Muscle spasms—Docetaxel—skin cancer	0.000354	0.00155	CcSEcCtD
Bromocriptine—Feeling abnormal—Fluorouracil—skin cancer	0.000343	0.0015	CcSEcCtD
Bromocriptine—Diarrhoea—Dactinomycin—skin cancer	0.000342	0.00149	CcSEcCtD
Bromocriptine—Vomiting—Bleomycin—skin cancer	0.000341	0.00149	CcSEcCtD
Bromocriptine—Rash—Bleomycin—skin cancer	0.000338	0.00148	CcSEcCtD
Bromocriptine—Dermatitis—Bleomycin—skin cancer	0.000337	0.00148	CcSEcCtD
Bromocriptine—Urticaria—Fluorouracil—skin cancer	0.000331	0.00145	CcSEcCtD
Bromocriptine—Syncope—Docetaxel—skin cancer	0.00033	0.00144	CcSEcCtD
Bromocriptine—Body temperature increased—Fluorouracil—skin cancer	0.000329	0.00144	CcSEcCtD
Bromocriptine—Asthenia—Temozolomide—skin cancer	0.000324	0.00142	CcSEcCtD
Bromocriptine—Loss of consciousness—Docetaxel—skin cancer	0.000324	0.00141	CcSEcCtD
Bromocriptine—ADRA2A—lymph node—skin cancer	0.000321	0.00328	CbGeAlD
Bromocriptine—Convulsion—Docetaxel—skin cancer	0.000319	0.00139	CcSEcCtD
Bromocriptine—Nausea—Bleomycin—skin cancer	0.000318	0.00139	CcSEcCtD
Bromocriptine—Hypertension—Docetaxel—skin cancer	0.000318	0.00139	CcSEcCtD
Bromocriptine—Vomiting—Dactinomycin—skin cancer	0.000318	0.00139	CcSEcCtD
Bromocriptine—ABCB1—lymphoid tissue—skin cancer	0.000317	0.00324	CbGeAlD
Bromocriptine—Rash—Dactinomycin—skin cancer	0.000315	0.00138	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000311	0.00136	CcSEcCtD
Bromocriptine—Diarrhoea—Temozolomide—skin cancer	0.000309	0.00135	CcSEcCtD
Bromocriptine—Dry mouth—Docetaxel—skin cancer	0.000306	0.00134	CcSEcCtD
Bromocriptine—ABCB1—female reproductive system—skin cancer	0.000306	0.00312	CbGeAlD
Bromocriptine—Confusional state—Docetaxel—skin cancer	0.000303	0.00132	CcSEcCtD
Bromocriptine—Oedema—Docetaxel—skin cancer	0.0003	0.00131	CcSEcCtD
Bromocriptine—Dizziness—Temozolomide—skin cancer	0.000299	0.00131	CcSEcCtD
Bromocriptine—Infection—Docetaxel—skin cancer	0.000298	0.00131	CcSEcCtD
Bromocriptine—Nausea—Dactinomycin—skin cancer	0.000297	0.0013	CcSEcCtD
Bromocriptine—Shock—Docetaxel—skin cancer	0.000296	0.00129	CcSEcCtD
Bromocriptine—Nervous system disorder—Docetaxel—skin cancer	0.000295	0.00129	CcSEcCtD
Bromocriptine—Tachycardia—Docetaxel—skin cancer	0.000293	0.00128	CcSEcCtD
Bromocriptine—Skin disorder—Docetaxel—skin cancer	0.000292	0.00128	CcSEcCtD
Bromocriptine—Vomiting—Temozolomide—skin cancer	0.000287	0.00126	CcSEcCtD
Bromocriptine—Anorexia—Docetaxel—skin cancer	0.000286	0.00125	CcSEcCtD
Bromocriptine—Rash—Temozolomide—skin cancer	0.000285	0.00125	CcSEcCtD
Bromocriptine—Diarrhoea—Fluorouracil—skin cancer	0.000285	0.00125	CcSEcCtD
Bromocriptine—Dermatitis—Temozolomide—skin cancer	0.000285	0.00124	CcSEcCtD
Bromocriptine—Headache—Temozolomide—skin cancer	0.000283	0.00124	CcSEcCtD
Bromocriptine—Hypotension—Docetaxel—skin cancer	0.000281	0.00123	CcSEcCtD
Bromocriptine—Dizziness—Fluorouracil—skin cancer	0.000275	0.0012	CcSEcCtD
Bromocriptine—Insomnia—Docetaxel—skin cancer	0.000272	0.00119	CcSEcCtD
Bromocriptine—Paraesthesia—Docetaxel—skin cancer	0.00027	0.00118	CcSEcCtD
Bromocriptine—Nausea—Temozolomide—skin cancer	0.000268	0.00117	CcSEcCtD
Bromocriptine—Dyspnoea—Docetaxel—skin cancer	0.000268	0.00117	CcSEcCtD
Bromocriptine—Somnolence—Docetaxel—skin cancer	0.000267	0.00117	CcSEcCtD
Bromocriptine—Vomiting—Fluorouracil—skin cancer	0.000265	0.00116	CcSEcCtD
Bromocriptine—Dyspepsia—Docetaxel—skin cancer	0.000264	0.00116	CcSEcCtD
Bromocriptine—Rash—Fluorouracil—skin cancer	0.000262	0.00115	CcSEcCtD
Bromocriptine—Dermatitis—Fluorouracil—skin cancer	0.000262	0.00115	CcSEcCtD
Bromocriptine—Decreased appetite—Docetaxel—skin cancer	0.000261	0.00114	CcSEcCtD
Bromocriptine—Headache—Fluorouracil—skin cancer	0.000261	0.00114	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000259	0.00113	CcSEcCtD
Bromocriptine—Fatigue—Docetaxel—skin cancer	0.000259	0.00113	CcSEcCtD
Bromocriptine—Constipation—Docetaxel—skin cancer	0.000257	0.00112	CcSEcCtD
Bromocriptine—ABCB1—head—skin cancer	0.000256	0.00261	CbGeAlD
Bromocriptine—Feeling abnormal—Docetaxel—skin cancer	0.000248	0.00108	CcSEcCtD
Bromocriptine—Nausea—Fluorouracil—skin cancer	0.000247	0.00108	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Docetaxel—skin cancer	0.000246	0.00107	CcSEcCtD
Bromocriptine—Body temperature increased—Docetaxel—skin cancer	0.000237	0.00104	CcSEcCtD
Bromocriptine—Abdominal pain—Docetaxel—skin cancer	0.000237	0.00104	CcSEcCtD
Bromocriptine—Asthenia—Docetaxel—skin cancer	0.000216	0.000943	CcSEcCtD
Bromocriptine—Diarrhoea—Docetaxel—skin cancer	0.000206	0.000899	CcSEcCtD
Bromocriptine—Dizziness—Docetaxel—skin cancer	0.000199	0.000869	CcSEcCtD
Bromocriptine—Vomiting—Docetaxel—skin cancer	0.000191	0.000835	CcSEcCtD
Bromocriptine—Rash—Docetaxel—skin cancer	0.000189	0.000828	CcSEcCtD
Bromocriptine—Dermatitis—Docetaxel—skin cancer	0.000189	0.000828	CcSEcCtD
Bromocriptine—Headache—Docetaxel—skin cancer	0.000188	0.000823	CcSEcCtD
Bromocriptine—ABCB1—lymph node—skin cancer	0.000179	0.00183	CbGeAlD
Bromocriptine—Nausea—Docetaxel—skin cancer	0.000178	0.00078	CcSEcCtD
Bromocriptine—ADRA2A—Signaling Pathways—SMO—skin cancer	2.08e-05	0.00031	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—TERT—skin cancer	2.06e-05	0.000306	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—TERT—skin cancer	2.05e-05	0.000306	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PLIN2—skin cancer	2.04e-05	0.000304	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—TERT—skin cancer	2.04e-05	0.000304	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	2.03e-05	0.000302	CbGpPWpGaD
Bromocriptine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.03e-05	0.000301	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—FOXO4—skin cancer	2e-05	0.000298	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—TERT—skin cancer	2e-05	0.000297	CbGpPWpGaD
Bromocriptine—ADRA2B—Hemostasis—KRAS—skin cancer	1.99e-05	0.000297	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—FOXO4—skin cancer	1.97e-05	0.000293	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—TERT—skin cancer	1.97e-05	0.000293	CbGpPWpGaD
Bromocriptine—DRD5—Signaling by GPCR—KRAS—skin cancer	1.93e-05	0.000288	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	1.93e-05	0.000287	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—ERCC2—skin cancer	1.88e-05	0.00028	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—TERT—skin cancer	1.88e-05	0.000279	CbGpPWpGaD
Bromocriptine—ADRA2C—Hemostasis—KRAS—skin cancer	1.86e-05	0.000277	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—ENO2—skin cancer	1.82e-05	0.00027	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	1.79e-05	0.000267	CbGpPWpGaD
Bromocriptine—ADRA2B—Hemostasis—TP53—skin cancer	1.77e-05	0.000264	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—TERT—skin cancer	1.77e-05	0.000263	CbGpPWpGaD
Bromocriptine—ADRA2A—Hemostasis—NRAS—skin cancer	1.76e-05	0.000261	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—TERT—skin cancer	1.75e-05	0.00026	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—TERT—skin cancer	1.75e-05	0.00026	CbGpPWpGaD
Bromocriptine—HTR6—Signaling by GPCR—NRAS—skin cancer	1.73e-05	0.000258	CbGpPWpGaD
Bromocriptine—HTR7—Signaling by GPCR—NRAS—skin cancer	1.73e-05	0.000258	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—NRAS—skin cancer	1.72e-05	0.000256	CbGpPWpGaD
Bromocriptine—ADRA2B—Hemostasis—HRAS—skin cancer	1.69e-05	0.000252	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—NRAS—skin cancer	1.68e-05	0.000251	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—NRAS—skin cancer	1.66e-05	0.000247	CbGpPWpGaD
Bromocriptine—ADRA2C—Hemostasis—TP53—skin cancer	1.65e-05	0.000246	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—CSPG4—skin cancer	1.65e-05	0.000245	CbGpPWpGaD
Bromocriptine—DRD5—Signaling by GPCR—HRAS—skin cancer	1.64e-05	0.000244	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—BRAF—skin cancer	1.63e-05	0.000242	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—BRAF—skin cancer	1.63e-05	0.000242	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—BRAF—skin cancer	1.62e-05	0.000241	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—TERT—skin cancer	1.59e-05	0.000237	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—BRAF—skin cancer	1.58e-05	0.000236	CbGpPWpGaD
Bromocriptine—ADRA2C—Hemostasis—HRAS—skin cancer	1.58e-05	0.000235	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.58e-05	0.000235	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—TERT—skin cancer	1.58e-05	0.000235	CbGpPWpGaD
Bromocriptine—DRD5—Signaling by GPCR—IL6—skin cancer	1.57e-05	0.000234	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—BRAF—skin cancer	1.56e-05	0.000232	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—ERCC2—skin cancer	1.53e-05	0.000227	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—TERT—skin cancer	1.52e-05	0.000227	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—TERT—skin cancer	1.51e-05	0.000225	CbGpPWpGaD
Bromocriptine—ADRA2A—Hemostasis—KRAS—skin cancer	1.51e-05	0.000225	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—NRAS—skin cancer	1.49e-05	0.000222	CbGpPWpGaD
Bromocriptine—HTR6—Signaling by GPCR—KRAS—skin cancer	1.49e-05	0.000222	CbGpPWpGaD
Bromocriptine—HTR7—Signaling by GPCR—KRAS—skin cancer	1.49e-05	0.000222	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—BRAF—skin cancer	1.49e-05	0.000221	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—KRAS—skin cancer	1.48e-05	0.00022	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—TERT—skin cancer	1.47e-05	0.000219	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—NRAS—skin cancer	1.47e-05	0.000219	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—NRAS—skin cancer	1.47e-05	0.000219	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—ENO2—skin cancer	1.45e-05	0.000216	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—TERT—skin cancer	1.45e-05	0.000216	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—KRAS—skin cancer	1.45e-05	0.000216	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—KRAS—skin cancer	1.43e-05	0.000212	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—BRAF—skin cancer	1.4e-05	0.000209	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—BRAF—skin cancer	1.38e-05	0.000206	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—BRAF—skin cancer	1.38e-05	0.000206	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.36e-05	0.000203	CbGpPWpGaD
Bromocriptine—ADRA2A—Hemostasis—TP53—skin cancer	1.34e-05	0.0002	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—NRAS—skin cancer	1.34e-05	0.0002	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—TERT—skin cancer	1.34e-05	0.000199	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.33e-05	0.000198	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—NRAS—skin cancer	1.33e-05	0.000197	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—TERT—skin cancer	1.32e-05	0.000196	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—TERT—skin cancer	1.29e-05	0.000192	CbGpPWpGaD
Bromocriptine—ADRA2A—Hemostasis—HRAS—skin cancer	1.29e-05	0.000191	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—KRAS—skin cancer	1.28e-05	0.000191	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.28e-05	0.000191	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.28e-05	0.00019	CbGpPWpGaD
Bromocriptine—HTR6—Signaling by GPCR—HRAS—skin cancer	1.27e-05	0.000189	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—KRAS—skin cancer	1.27e-05	0.000188	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—KRAS—skin cancer	1.27e-05	0.000188	CbGpPWpGaD
Bromocriptine—HTR7—Signaling by GPCR—HRAS—skin cancer	1.27e-05	0.000188	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—BRAF—skin cancer	1.26e-05	0.000188	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—HRAS—skin cancer	1.26e-05	0.000187	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.25e-05	0.000186	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.24e-05	0.000185	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—HRAS—skin cancer	1.23e-05	0.000183	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—NRAS—skin cancer	1.22e-05	0.000182	CbGpPWpGaD
Bromocriptine—HTR6—Signaling by GPCR—IL6—skin cancer	1.21e-05	0.000181	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—HRAS—skin cancer	1.21e-05	0.00018	CbGpPWpGaD
Bromocriptine—HTR7—Signaling by GPCR—IL6—skin cancer	1.21e-05	0.00018	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—BRAF—skin cancer	1.21e-05	0.000179	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—IL6—skin cancer	1.2e-05	0.000179	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—BRAF—skin cancer	1.2e-05	0.000178	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—TERT—skin cancer	1.2e-05	0.000178	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—IL6—skin cancer	1.18e-05	0.000175	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.17e-05	0.000174	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—IL6—skin cancer	1.16e-05	0.000173	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.16e-05	0.000172	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—KRAS—skin cancer	1.15e-05	0.000172	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—BRAF—skin cancer	1.15e-05	0.000171	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.14e-05	0.00017	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—KRAS—skin cancer	1.14e-05	0.00017	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.13e-05	0.000169	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—PTGS2—skin cancer	1.13e-05	0.000168	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—NRAS—skin cancer	1.13e-05	0.000168	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—ENO2—skin cancer	1.12e-05	0.000167	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.11e-05	0.000165	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—IL6—skin cancer	1.11e-05	0.000165	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.1e-05	0.000164	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.1e-05	0.000163	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—HRAS—skin cancer	1.09e-05	0.000162	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	1.09e-05	0.000161	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—HRAS—skin cancer	1.08e-05	0.00016	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—HRAS—skin cancer	1.08e-05	0.00016	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.07e-05	0.000159	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—BRAF—skin cancer	1.06e-05	0.000158	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—ERCC2—skin cancer	1.06e-05	0.000157	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—KRAS—skin cancer	1.05e-05	0.000156	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—IL6—skin cancer	1.04e-05	0.000155	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—BRAF—skin cancer	1.04e-05	0.000155	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—IL6—skin cancer	1.03e-05	0.000153	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—IL6—skin cancer	1.03e-05	0.000153	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—NRAS—skin cancer	1.02e-05	0.000152	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—NRAS—skin cancer	1.02e-05	0.000152	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—BRAF—skin cancer	1.02e-05	0.000152	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—NRAS—skin cancer	1.02e-05	0.000151	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—TP53—skin cancer	1.01e-05	0.000151	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.01e-05	0.00015	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—NRAS—skin cancer	9.95e-06	0.000148	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—HRAS—skin cancer	9.81e-06	0.000146	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—NRAS—skin cancer	9.79e-06	0.000146	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—HRAS—skin cancer	9.72e-06	0.000145	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—HRAS—skin cancer	9.7e-06	0.000144	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—KRAS—skin cancer	9.69e-06	0.000144	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—KRAS—skin cancer	9.54e-06	0.000142	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—BRAF—skin cancer	9.48e-06	0.000141	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—IL6—skin cancer	9.39e-06	0.00014	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—HRAS—skin cancer	9.38e-06	0.00014	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—NRAS—skin cancer	9.34e-06	0.000139	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	9.34e-06	0.000139	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—HRAS—skin cancer	9.34e-06	0.000139	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—IL6—skin cancer	9.3e-06	0.000138	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—IL6—skin cancer	9.29e-06	0.000138	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—PTGS2—skin cancer	9.15e-06	0.000136	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—HRAS—skin cancer	9.08e-06	0.000135	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—IL6—skin cancer	8.98e-06	0.000134	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—HRAS—skin cancer	8.94e-06	0.000133	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—IL6—skin cancer	8.94e-06	0.000133	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—NRAS—skin cancer	8.81e-06	0.000131	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—KRAS—skin cancer	8.81e-06	0.000131	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—KRAS—skin cancer	8.8e-06	0.000131	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—KRAS—skin cancer	8.74e-06	0.00013	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—NRAS—skin cancer	8.69e-06	0.000129	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—NRAS—skin cancer	8.69e-06	0.000129	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—IL6—skin cancer	8.69e-06	0.000129	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	8.68e-06	0.000129	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—KRAS—skin cancer	8.56e-06	0.000127	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—IL6—skin cancer	8.55e-06	0.000127	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—ERCC2—skin cancer	8.43e-06	0.000125	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—KRAS—skin cancer	8.42e-06	0.000125	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—HRAS—skin cancer	8.24e-06	0.000123	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—HRAS—skin cancer	8.11e-06	0.000121	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—KRAS—skin cancer	8.04e-06	0.00012	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	7.94e-06	0.000118	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—NRAS—skin cancer	7.92e-06	0.000118	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—IL6—skin cancer	7.89e-06	0.000117	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—NRAS—skin cancer	7.85e-06	0.000117	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—TP53—skin cancer	7.83e-06	0.000117	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—TP53—skin cancer	7.82e-06	0.000116	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—TP53—skin cancer	7.77e-06	0.000116	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—IL6—skin cancer	7.76e-06	0.000115	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—TP53—skin cancer	7.61e-06	0.000113	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—IL6—skin cancer	7.6e-06	0.000113	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—KRAS—skin cancer	7.58e-06	0.000113	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—NRAS—skin cancer	7.58e-06	0.000113	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—NRAS—skin cancer	7.54e-06	0.000112	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—HRAS—skin cancer	7.49e-06	0.000111	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—TP53—skin cancer	7.49e-06	0.000111	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—KRAS—skin cancer	7.48e-06	0.000111	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—KRAS—skin cancer	7.48e-06	0.000111	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—HRAS—skin cancer	7.48e-06	0.000111	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—HRAS—skin cancer	7.43e-06	0.000111	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	7.38e-06	0.00011	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—NRAS—skin cancer	7.33e-06	0.000109	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—HRAS—skin cancer	7.28e-06	0.000108	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—NRAS—skin cancer	7.22e-06	0.000107	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—IL6—skin cancer	7.17e-06	0.000107	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—HRAS—skin cancer	7.16e-06	0.000107	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—IL6—skin cancer	7.16e-06	0.000107	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—TP53—skin cancer	7.15e-06	0.000106	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—IL6—skin cancer	7.11e-06	0.000106	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—IL6—skin cancer	7.06e-06	0.000105	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—IL6—skin cancer	6.96e-06	0.000104	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—IL6—skin cancer	6.85e-06	0.000102	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—HRAS—skin cancer	6.84e-06	0.000102	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—KRAS—skin cancer	6.82e-06	0.000101	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—KRAS—skin cancer	6.76e-06	0.000101	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—TP53—skin cancer	6.74e-06	0.0001	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—NRAS—skin cancer	6.65e-06	9.9e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—TP53—skin cancer	6.65e-06	9.9e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—TP53—skin cancer	6.65e-06	9.9e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—NRAS—skin cancer	6.55e-06	9.74e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—IL6—skin cancer	6.54e-06	9.74e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—KRAS—skin cancer	6.52e-06	9.7e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—ERCC2—skin cancer	6.5e-06	9.68e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—KRAS—skin cancer	6.49e-06	9.65e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—HRAS—skin cancer	6.45e-06	9.59e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—NRAS—skin cancer	6.41e-06	9.54e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—HRAS—skin cancer	6.36e-06	9.46e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—HRAS—skin cancer	6.36e-06	9.46e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PTGS2—skin cancer	6.33e-06	9.42e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—KRAS—skin cancer	6.31e-06	9.39e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—KRAS—skin cancer	6.21e-06	9.24e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—IL6—skin cancer	6.17e-06	9.18e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—IL6—skin cancer	6.09e-06	9.06e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—IL6—skin cancer	6.09e-06	9.06e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—TP53—skin cancer	6.06e-06	9.02e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—TP53—skin cancer	6e-06	8.93e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—NRAS—skin cancer	5.96e-06	8.86e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—TP53—skin cancer	5.8e-06	8.63e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—HRAS—skin cancer	5.8e-06	8.62e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—TP53—skin cancer	5.77e-06	8.58e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—HRAS—skin cancer	5.74e-06	8.54e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—KRAS—skin cancer	5.73e-06	8.52e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—KRAS—skin cancer	5.63e-06	8.38e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—TP53—skin cancer	5.61e-06	8.35e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—IL6—skin cancer	5.55e-06	8.25e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—HRAS—skin cancer	5.54e-06	8.25e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—TP53—skin cancer	5.52e-06	8.21e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—KRAS—skin cancer	5.52e-06	8.21e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—HRAS—skin cancer	5.51e-06	8.21e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—IL6—skin cancer	5.5e-06	8.18e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—HRAS—skin cancer	5.36e-06	7.98e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—IL6—skin cancer	5.31e-06	7.89e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—HRAS—skin cancer	5.28e-06	7.86e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—IL6—skin cancer	5.28e-06	7.85e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—IL6—skin cancer	5.13e-06	7.64e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—KRAS—skin cancer	5.13e-06	7.63e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—TP53—skin cancer	5.09e-06	7.57e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PTGS2—skin cancer	5.05e-06	7.52e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—IL6—skin cancer	5.05e-06	7.52e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—TP53—skin cancer	5.01e-06	7.45e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—TP53—skin cancer	4.9e-06	7.3e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—HRAS—skin cancer	4.87e-06	7.24e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—HRAS—skin cancer	4.79e-06	7.13e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—HRAS—skin cancer	4.69e-06	6.98e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—IL6—skin cancer	4.66e-06	6.93e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—IL6—skin cancer	4.58e-06	6.82e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—TP53—skin cancer	4.56e-06	6.78e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—IL6—skin cancer	4.49e-06	6.68e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—HRAS—skin cancer	4.36e-06	6.48e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—IL6—skin cancer	4.17e-06	6.21e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PTGS2—skin cancer	3.9e-06	5.8e-05	CbGpPWpGaD
